Artivion, Inc. (AORT)

24,08 +0,52 (+2,23%) A partir del 03:02PM EDT. Mercado abierto.

Artivion, Inc.

1655 Roberts Boulevard N.W.
Kennesaw, GA 30144
United States
770 419 3355
https://artivion.com

Sector(es): Healthcare
Sector: Medical Devices
Empleados a tiempo completo: 1500

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. James Patrick Mackin	Chairman, President & CEO	2,37M	194,62k	1967
Mr. Lance A. Berry CPA	Executive VP of Finance, COO & CFO	138,36k	N/A	1972
Ms. Amy D. Horton CPA	VP & Chief Accounting Officer	621,26k	118,2k	1970
Ms. Jean F. Holloway Esq.	Senior VP, General Counsel, Chief Compliance Officer & Corporate Secretary	841,43k	N/A	1957
Mr. John E. Davis	Senior VP & Chief Commercial Officer	802,02k	27,55k	1965
Mr. Matthew A. Getz	VP of Human Resources & Chief Human Resources Officer	N/A	N/A	1969
Dr. Marshall S. Stanton M.D.	Senior VP of Clinical Research & Chief Medical Officer	615,55k	N/A	1957
Dr. Robert C. Thomson	Vice President of Research & Development	N/A	N/A	1970
Mr. Florian Tyrs	Vice President of Global Operations	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.

Gobierno corporativo

El ISS Governance QualityScore de Artivion, Inc., a día 1 de junio de 2024, es 3. Las puntuaciones base son Auditoría: 3; Tablero: 5; Derechos de los accionistas: 4; Compensación: 3.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.